Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›SYLVANT 400 mg powder for concentrate for solution for infusion
Medicines register · Ireland

SYLVANT 400 mg powder for concentrate for solution for infusion

Authorisation EU/1/14/928/002 · EUSA Pharma (Netherlands) B.V.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
EUSA Pharma (Netherlands) B.V. (all products →)
Active substance
Siltuximab
Clinical trials
4 clinical trials →
Dosage form
Powder for concentrate for solution for infusion
Route of administration
Intravenous use
ATC codes
L04AC, L04AC11
First authorised
22/05/2014
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Siltuximab: supply and approvals

2 authorised products on the HPRA list contain Siltuximab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 928. It has been authorised for 12 years (since 22 May 2014). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Siltuximab in Ireland

1 other product on the HPRA list contains Siltuximab, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
SYLVANT 100 mg powder for concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.Centralised EU authorisationNot stated

Other substances in ATC group L04AC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 10 other active substances share the group L04AC with this product:

Secukinumab (3) · Canakinumab (2) · Sarilumab (2) · Basiliximab (2) · Ixekizumab (2) · Anakinra (1) · Brodalumab (1) · Tocilizumab (1) · RISANKIZUMAB (1) · Spesolimab (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

EUSA Pharma (Netherlands) B.V. holds 5 products on the HPRA list, with 3 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.